2. Academic Validation
  3. Design, synthesis and activity evaluation of a novel PPARα agonist based on virtual screening

Design, synthesis and activity evaluation of a novel PPARα agonist based on virtual screening

  • Bioorg Med Chem Lett. 2026 Jun:135:130585. doi: 10.1016/j.bmcl.2026.130585.
Yutong Niu 1,  Weinan Wang 2,  Yiqian Xie 1,  Li Zhang 3,  Xingyong Liu 3,  Likun Gong 4,  Jing Chen 5,  Zhili Zuo 6
Affiliations

Affiliations

  • 1 School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, China; Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, UCAS, Hangzhou 310024, China.
  • 2 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210046, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 3 School of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, China.
  • 4 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210046, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: lkgong@simm.ac.cn.
  • 5 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210046, China; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: jchen@simm.ac.cn.
  • 6 Zhejiang Key Laboratory of Intelligent Drug Discovery and Development, School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, UCAS, Hangzhou 310024, China. Electronic address: zlzuo@ucas.ac.cn.
PMID: 41692311 DOI: 10.1016/j.bmcl.2026.130585
Abstract

Peroxisome Proliferator-activated Receptor α (PPARα) represents a critical therapeutic target for dyslipidemia. To discover novel scaffold agonists, we used Pemafibrate as a template to construct a focused chemical library with the infiniSee software. An integrated virtual screening approach, including molecular docking, MM-GBSA binding free energy calculations, ADMET profiling, and visual inspection, was applied to identify a hit compound. Subsequent structural optimization led to the synthesis of 40 derivatives. Among the tested compounds, XYQ3-B11 was identified as the most potent PPARα Activator. In the luciferase reporter assay, XYQ3-B11 exhibited an EC50 value of 8.33 μM, better than the reference agonist WY14643 (EC50 = 16.10 μM). Notably, XYQ3-B11 possesses a distinctive hybrid architecture, comprising a central pyridine ring, a 2-fluorobenzoate moiety, and an indole-derived side chain. These findings highlight XYQ3-B11 as a promising novel chemotype for the start of development of PPARα agonists.

Keywords

PPARα agonist; Structural modification; Synthesis; Virtual screening.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z